Should I buy or sell Evolent Health stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EVH shares. View EVH analyst ratings or view top-rated stocks .

What is Evolent Health's stock price target for 2024?

11 Wall Street research analysts have issued twelve-month price objectives for Evolent Health's stock. Their EVH share price targets range from $34.00 to $52.00. On average, they anticipate the company's share price to reach $43.00 in the next year. This suggests a possible upside of 45.7% from the stock's current price. View analysts price targets for EVH or view top-rated stocks among Wall Street analysts .

How have EVH shares performed in 2024?

Evolent Health's stock was trading at $33.03 on January 1st, 2024. Since then, EVH stock has decreased by 10.7% and is now trading at $29.51. View the best growth stocks for 2024 here .

When is Evolent Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EVH earnings forecast .

How can I listen to Evolent Health's earnings call?

Evolent Health will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Evolent Health's earnings last quarter?

Evolent Health, Inc. (NYSE:EVH) issued its quarterly earnings data on Thursday, February, 22nd. The technology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.13. The technology company earned $556.06 million during the quarter, compared to analyst estimates of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive trailing twelve-month return on equity of 6.60%.

What ETFs hold Evolent Health's stock?

ETFs with the largest weight of Evolent Health (NYSE:EVH) stock in their portfolio include Fidelity Digital Health ETF (FDHT) , Harbor Corporate Culture Small Cap ETF (HAPS) and Fidelity Disruptive Medicine ETF (FMED) . Harbor Small Cap Explorer ETF (QWST) .

What guidance has Evolent Health issued on next quarter's earnings?

Evolent Health updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.4 billion-$2.5 billion, compared to the consensus revenue estimate of $2.3 billion.

What is Seth Blackley's approval rating as Evolent Health's CEO?

12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com . Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolent Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include Xtrackers California Municipal Bond ETF (CA) , BlackRock (BLK) , Universal Insurance (UVE) , Endologix (ELGX) , Advanced Micro Devices (AMD) , Energy Transfer (ET) , Chipotle Mexican Grill (CMG) , Ford Motor (F) , Cisco Systems (CSCO) and Heron Therapeutics (HRTX) .

When did Evolent Health IPO?

Evolent Health (EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Who are Evolent Health's major shareholders?

Evolent Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hodges Capital Management Inc. (0.41%), Salem Investment Counselors Inc. (0.10%), ERn Financial LLC (0.05%), WoodTrust Financial Corp (0.04%), First Dallas Securities Inc. (0.01%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Cheryl Scott , Daniel Joseph Mccarthy , Diane Holder , Frank J Williams, Frank J Williams , John Paul Johnson , Jonathan Weinberg , Mary Bridget Duffy , Seth Blackley , Simon Maisey and Steve Tutewohl . View institutional ownership trends .

How do I buy shares of Evolent Health?

Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NYSE:EVH

Evolent Health (EVH) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free EVH Stock Alerts

$29.51

-0.11 (-0.37%)

(As of 04/19/2024 ET)

Compare

Today's Range: $29.06
▼
$29.73
50-Day Range: $29.51
▼
$34.74
52-Week Range: $23.33
▼
$36.70

Volume: 733,296 shs
Average Volume: 951,065 shs
Market Capitalization: $3.41 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.00

Get Evolent Health alerts:

Evolent Health MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.91 Rating Score
Upside/Downside: 45.7% Upside
$43.00 Price Target
Short Interest: Bearish
9.19% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.24
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 58.62%
From $0.87 to $1.38 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.50 out of 5 stars

Computer And Technology Sector

485th out of 585 stocks

Management Services Industry

5th out of 5 stocks

3.5

Analyst's Opinion

Consensus Rating
Evolent Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Evolent Health has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.19% of the outstanding shares of Evolent Health have been sold short.
Short Interest Ratio / Days to Cover
Evolent Health has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.
Change versus previous month
Short interest in Evolent Health has recently decreased by 1.85%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Evolent Health does not currently pay a dividend.
Dividend Growth
Evolent Health does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for EVH.

1.5

News and Social Media Coverage

News Sentiment
Evolent Health has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Computer and Technology companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Evolent Health this week, compared to 3 articles on an average week.
Search Interest
2 people have searched for EVH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Evolent Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Evolent Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Evolent Health is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Evolent Health are expected to grow by 58.62% in the coming year, from $0.87 to $1.38 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Evolent Health is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Evolent Health is -23.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Evolent Health has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Evolent Health Stock (NYSE:EVH)

Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.

EVH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVH Stock News Headlines

April 18, 2024 | investing.com

Evolent Health stock maintains price target with Overweight rating

April 18, 2024 | prnewswire.com

Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 15, 2024 | finance.yahoo.com

Evolent Health, Inc. (EVH)

April 7, 2024 | finance.yahoo.com

Recent 7.4% pullback isn't enough to hurt long-term Evolent Health (NYSE:EVH) shareholders, they're still up 134% over 5 years

March 16, 2024 | finance.yahoo.com

EVH Apr 2024 27.500 put

March 15, 2024 | markets.businessinsider.com

Navigating 4 Analyst Ratings For Evolent Health

March 1, 2024 | msn.com

Oppenheimer Initiates Coverage of Evolent Health (EVH) with Outperform Recommendation

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

February 27, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know

February 26, 2024 | finance.yahoo.com

Here's What Analysts Are Forecasting For Evolent Health, Inc. (NYSE:EVH) After Its Annual Results

February 24, 2024 | finance.yahoo.com

Evolent Health Full Year 2023 Earnings: EPS Misses Expectations

February 23, 2024 | markets.businessinsider.com

These Analysts Revise Their Forecasts On Evolent Health After Upbeat Results

February 23, 2024 | markets.businessinsider.com

Analyst Scoreboard: 4 Ratings For Evolent Health

February 23, 2024 | finanznachrichten.de

Evolent Health: Evolent Announces Fourth Quarter and Full Year 2023 Results

February 23, 2024 | markets.businessinsider.com

Barclays Reaffirms Their Buy Rating on Evolent Health (EVH)

February 23, 2024 | markets.businessinsider.com

Evolent Health (EVH) Buy Rating Affirmed Amid Strong Q4 Results and Promising 2024 Projections

February 23, 2024 | investing.com

Evolent Health Inc (EVH)

February 22, 2024 | benzinga.com

Evolent Health Stock (NYSE:EVH) Insider Trades

February 22, 2024 | finance.yahoo.com

Evolent Health Inc (EVH) Reports Robust Revenue Growth and Improved Adjusted EBITDA in 2023

February 22, 2024 | prnewswire.com

Evolent Announces Fourth Quarter and Full Year 2023 Results

February 22, 2024 | benzinga.com

Evolent Health Stock (NYSE:EVH) Dividends: History, Yield and Dates

February 20, 2024 | msn.com

Teladoc Health slides ~16% after hours as 2024 guidance, long-term outlook disappoints

February 15, 2024 | seekingalpha.com

EVH Evolent Health, Inc.

February 14, 2024 | finance.yahoo.com

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

February 14, 2024 | prnewswire.com

Evolent Adds Russell Glass, Headspace CEO, to Board of Directors

January 31, 2024 | markets.businessinsider.com

Positive Outlook for Evolent Health with Anticipated EBITDA Growth and Strategic Deals Reinforcing Buy Rating

See More Headlines

Receive EVH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolent Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Confirmed): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Computer and Technology
Industry: Management services
Sub-Industry: N/A
Current Symbol: NYSE:EVH
CUSIP: N/A
CIK: 1628908
Web: www.evolenthealth.com
Phone: (571) 389-6000
Fax: 571-389-6001
Employees: 4,700
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $43.00
High Stock Price Target: $52.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +45.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.91
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 33.92
P/E Growth: N/A
Net Income: $-113,040,000.00
Net Margins: -5.76%
Pretax Margin: -10.31%
Return on Equity: 6.60%
Return on Assets: 2.73%

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 1.01
Quick Ratio: 1.01

Sales & Book Value

Annual Sales: $1.96 billion
Price / Sales: 1.73
Cash Flow: $1.78 per share
Price / Cash Flow: 16.60
Book Value: $9.38 per share
Price / Book: 3.15

Miscellaneous

Outstanding Shares: 115,430,000
Free Float: 111,621,000
Market Cap: $3.41 billion
Optionable: Optionable
Beta: 1.53

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Seth Barrie Blackley (Age 45)
Co-Founder, CEO & Director
Comp: $1.79M
Mr. Dan McCarthy (Age 39)
CEO of New Century Health & President
Comp: $1.29M
Mr. John Paul Johnson (Age 40)
Chief Financial Officer
Comp: $994.22k
Mr. Jonathan David Weinberg J.D. (Age 56)
Chief Legal Officer, General Counsel & Secretary
Comp: $696.07k
Ms. Emily Rafferty (Age 41)
Chief Operating Officer
Mr. Aammaad Shams (Age 40)
Chief Accounting Officer
Comp: $341.78k
Mr. Robert Cruz
Chief Technology Officer
Ms. Jessica White
Chief Information Officer
Mr. Seth R. Frank
Vice President of Investor Relations
Ms. Kali Beyah
Chief People & Brand Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EVH Stock Analysis - Frequently Asked Questions

Should I buy or sell Evolent Health stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EVH shares.
View EVH analyst ratings or view top-rated stocks.
What is Evolent Health's stock price target for 2024?: 11 Wall Street research analysts have issued twelve-month price objectives for Evolent Health's stock. Their EVH share price targets range from $34.00 to $52.00. On average, they anticipate the company's share price to reach $43.00 in the next year. This suggests a possible upside of 45.7% from the stock's current price.
View analysts price targets for EVH or view top-rated stocks among Wall Street analysts.
How have EVH shares performed in 2024?: Evolent Health's stock was trading at $33.03 on January 1st, 2024. Since then, EVH stock has decreased by 10.7% and is now trading at $29.51.
View the best growth stocks for 2024 here.
When is Evolent Health's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EVH earnings forecast.
How can I listen to Evolent Health's earnings call?: Evolent Health will be holding an earnings conference call on Thursday, May 9th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Evolent Health's earnings last quarter?: Evolent Health, Inc. (NYSE:EVH) issued its quarterly earnings data on Thursday, February, 22nd. The technology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.13. The technology company earned $556.06 million during the quarter, compared to analyst estimates of $541.87 million. Evolent Health had a negative net margin of 5.76% and a positive trailing twelve-month return on equity of 6.60%.
What ETFs hold Evolent Health's stock?: ETFs with the largest weight of Evolent Health (NYSE:EVH) stock in their portfolio include Fidelity Digital Health ETF (FDHT), Harbor Corporate Culture Small Cap ETF (HAPS) and Fidelity Disruptive Medicine ETF (FMED).Harbor Small Cap Explorer ETF (QWST).

What guidance has Evolent Health issued on next quarter's earnings?: Evolent Health updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.4 billion-$2.5 billion, compared to the consensus revenue estimate of $2.3 billion.
What is Seth Blackley's approval rating as Evolent Health's CEO?: 12 employees have rated Evolent Health Chief Executive Officer Seth Blackley on Glassdoor.com. Seth Blackley has an approval rating of 100% among the company's employees. This puts Seth Blackley in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Evolent Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Energy Transfer (ET), Chipotle Mexican Grill (CMG), Ford Motor (F), Cisco Systems (CSCO) and Heron Therapeutics (HRTX).
When did Evolent Health IPO?: Evolent Health (EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.
Who are Evolent Health's major shareholders?: Evolent Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Hodges Capital Management Inc. (0.41%), Salem Investment Counselors Inc. (0.10%), ERn Financial LLC (0.05%), WoodTrust Financial Corp (0.04%), First Dallas Securities Inc. (0.01%) and Banque Cantonale Vaudoise (0.00%). Insiders that own company stock include Cheryl Scott, Daniel Joseph Mccarthy, Diane Holder, Frank J Williams, Frank J Williams, John Paul Johnson, Jonathan Weinberg, Mary Bridget Duffy, Seth Blackley, Simon Maisey and Steve Tutewohl.
View institutional ownership trends.
How do I buy shares of Evolent Health?: Shares of EVH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EVH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Evolent Health (EVH) Stock Price, News & Analysis

Evolent Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Evolent Health Stock (NYSE:EVH)

EVH Stock Price History

EVH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EVH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™